Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

454
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
454
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

363
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
363
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

381
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
381
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

3.9K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
3.9K
Male Sexual Response: Erection & Ejaculation01:17

Male Sexual Response: Erection & Ejaculation

15.3K
Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
15.3K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

701
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
701

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interventional Radiology-Guided Foley Catheterization for Pelvic Fracture with Urethral Injury: A Single-Center Retrospective Case Series.

Journal of clinical medicine·2026
Same author

An artificial intelligence model integrating clinico-laboratory data and single nucleotide polymorphism-based genomic risk for prostate cancer diagnosis in Korean men.

Investigative and clinical urology·2026
Same author

Impact of bacteriospermia on sperm DNA fragmentation: a narrative review.

Translational andrology and urology·2026
Same author

Age-Related Testosterone Decline and Metabolic Determinants in 27,687 Korean Men Aged ≥40 Years: A Nationwide Population-Based Study.

The world journal of men's health·2026
Same author

Effects of Additional Administration of Vitamin D Formula with Anti-Muscarinic Agent for Patient with Overactive Bladder and Vitamin D Deficiency: A Double Blind Randomized Controlled Trial.

The world journal of men's health·2026
Same author

Effect of EphA2 Silencing on Inhibiting the Progression of Renal Cell Carcinoma in an Orthotopic Mouse Model.

Cells·2025

Related Experiment Video

Updated: Dec 25, 2025

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

681

Novel Emerging Therapies for Erectile Dysfunction.

Soyeun Kim1, Min Chul Cho2, Sung Yong Cho3

  • 1Department of Family Medicine, Korea Cancer Center Hospital, Seoul, Korea.

The World Journal of Men'S Health
|March 24, 2020
PubMed
Summary

Emerging erectile dysfunction (ED) therapies show promise for non-responders. Novel treatments like stem cell regeneration and shock wave therapy offer new hope for difficult-to-treat ED patients.

Keywords:
Erectile dysfunctionExtracorporeal shockwave therapyGuanylate cyclaseMelanocortinsNitric oxide donorStem cells

More Related Videos

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

3.8K
Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents
08:03

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents

Published on: June 6, 2018

14.9K

Related Experiment Videos

Last Updated: Dec 25, 2025

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

681
Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

3.8K
Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents
08:03

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents

Published on: June 6, 2018

14.9K

Area of Science:

  • Urology
  • Regenerative Medicine
  • Pharmacology

Background:

  • Erectile dysfunction (ED) affects many men, with a significant portion unresponsive to current treatments like PDE5 inhibitors.
  • Treatment failure in ED is linked to comorbidities, prior surgeries, and psychological factors.

Purpose of the Study:

  • To review novel and emerging therapeutic strategies for erectile dysfunction.
  • To explore potential treatments for patients with difficult-to-treat ED.

Main Methods:

  • Review of current medical literature on ED treatments.
  • Analysis of pre-clinical and clinical data on novel therapeutic agents and technologies.

Main Results:

  • Melanocortin receptor agonists show potential for initiating erections without sexual stimulation.
  • Peripherally acting agents (Max-K channel activators, guanylate cyclase activators, nitric oxide donors) may be effective alone or with PDE5 inhibitors.
  • Stem cell regeneration therapy demonstrates favorable outcomes in diabetic and post-prostatectomy ED.
  • Low-intensity shock wave therapy shows promise for vasculogenic ED.

Conclusions:

  • Emerging therapies, including regenerative medicine and novel pharmacological agents, offer new avenues for ED treatment.
  • Further well-designed clinical trials are necessary to validate the long-term safety and efficacy of these novel ED therapies.